Shares of the biotech fell around 15% on news the FDA is not only taking longer to review the drug, but will assemble an ...

A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design ...

Iowa, suggested Congress could once again move to overhaul PBMs’ controversial business practices after legislators pass ...

The French drugmaker joined several peers in promising new investments in U.S. drug production, but cautioned plans could ...

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...